Watch out Bristol Myers, Merck is right on your heels with more positive Keytruda data to take to the FDA
Merck announced positive Phase III results to back yet another indication for cash cow Keytruda — this time as a first-line esophageal cancer treatment in combination …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.